Janssen to Focus on Retinal Diseases with Multi-part MeiraGTx Deal
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 2 (Table of Contents)
Published: 9 Feb-2019
DOI: 10.3833/pdr.v2019.i2.2404 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Less than a year after its US$75 M initial public offering, UK based MeiraGTx has entered into a multi-part collaboration, option and licence agreement with Janssen Pharmaceuticals for the development of gene therapies to treat inherited retinal diseases (IRDs)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS